Fig 1: Expression of genes for TGF-βRII (A), TGF-β1 (B), SMAD4 (C) in tissues of CRC patients compared with other types of GIT tumors (MTG: Malignant tumor group; BTG: Benign tumor group; TPM: Transcript per million; COAD: Colorectal Adenocarcinoma; ESCA: Esophageal carcinoma; LIHC: Liver hepatocellular carcinoma; PAAD: Pancreatic adenocarcinoma; STAD: Stomach adenocarcinoma; *: p < 0,05).
Fig 2: Gene expression for TGF-βR2 (A), TGF-β1 (B), and SMAD4 (C) in CRC patients divided into different clinical stages (TPM: Transcript per million).
Fig 3: Survival curves as a function of gene expression for TGF-βRII (A), TGF-β1 (B), and SMAD4 (C) in CRC patients (TPM: Transcript per million).
Fig 4: Expression of tissue TGF-βRII (I), TGF-β1 (II), and SMAD4 (III) in CRC patients divided according to TNM classification markers and gender (A-males and B-females) patients.
Fig 5: SMAD4 proteins (60 kDa) confirmed in patients divided according to TNM classification. (BTG: Benign tumor group). *Patients whose SMAD 4 expression most closely reflects the group of patients at the given stage were selected.
Supplier Page from Abcam for Human SMAD4 ELISA Kit